Circulating levels of CSF-1 (M-CSF) a lymphohematopoietic cytokine may be a useful marker of disease status in patients with malignant ovarian neoplasms

Kacinski BM, B M Kacinski, Barry M. Kacinski, Stanley ER, E. Richard Stanley, E R Stanley, D Carter, Carter D, Darryl Carter, Joseph T. Chambers, J T Chambers, Chambers JT, S K Chambers, Setsuko K. Chambers, Chambers SK, Ernest I. Kohorn, Kohorn EI, E I Kohorn, Peter E. Schwartz, P E Schwartz, Schwartz PE
International journal of radiation oncology, biology, physics · 1989 · vol. 17(1) , pp. 159–164 · doi:10.1016/0360-3016(89)90383-0 · PMID:2663797 · W2033424543
article OA: closed CC0 ⤵ 2 in-corpus citations
View on OpenAlex View on PubMed View at publisher
⚙ AI-generated summary by claude@2026-06, 2026-06-08 ⓘ

This study investigated circulating CSF-1 levels as a potential marker for disease status in patients with malignant ovarian neoplasms.

One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works

Abstract

We have previously reported our observations of epithelial tumor cell expression of transcripts and protein antigens of CSF-1 and transcripts of a protein closely related--if not identical--to the CSF-1 receptor in ovarian and endometrial neoplasms in vivo and in vitro. In the present communication, we extend these investigations to analyze the clinical utility of determinations of plasma CSF-1 concentrations in 125 samples from 33 patients with ovarian neoplasms and one patient with benign endometriosis. We observed that plasma CSF-1 levels in patients with active and recurrent neoplastic disease were markedly elevated and follow changes in disease status in individual patients. These and other results presented in this communication suggest that not only could CSF-1 be a useful circulating tumor marker in ovarian carcinoma patients, but also that in combination with measurements of other markers--such as CA-125--determinations of plasma CSF-1 levels might actually improve the accuracy of "tumor marker"-based assessments of disease status in patients with malignant ovarian neoplasms.

My notes (saved in your browser only)

MeSH descriptors

Biomarkers, Tumor Colony-Stimulating Factors Ovarian Neoplasms Adenocarcinoma Adenocarcinoma Adenocarcinoma Antigens, Tumor-Associated, Carbohydrate Antigens, Tumor-Associated, Carbohydrate Biomarkers, Tumor Colony-Stimulating Factors Female Humans Macrophage Colony-Stimulating Factor Neoplasm Invasiveness Neoplasm Staging Ovarian Neoplasms Ovarian Neoplasms Predictive Value of Tests Radioimmunoassay

Citation neighborhood (sparse)

Too few in-corpus citations on either side for a chart; here are the lists.

Cited by (2)

References (19)

Cited by (2)

Source provenance

europepmc
last seen: 2026-07-29T06:27:48.050232+00:00
openalex
last seen: 2026-06-04T00:00:01.174412+00:00
pubmed
last seen: 2026-05-13T22:09:10.744835+00:00
License: CC0 · commercial use OK